European journal of gynaecological oncology最新文献

{"title":"Vulvar cancer in young woman—case report","authors":"","doi":"10.22514/ejgo.2023.070","DOIUrl":"https://doi.org/10.22514/ejgo.2023.070","url":null,"abstract":"Vulvar cancer is rare with incidence of 45,240 new cases globally which account for 4% of all genitourinary tract neoplasma. It is considered as a postmenopausal disease, however incidence age has decreased over the years because of high prevalence of persistent high-risk human papillomavirus (hrHPV) infection. Vulvar cancer diagnosis in young women is challenging. Prompt and adequate diagnosis, and treatment can ensure the life quality. A 23 years old patient was admitted to Department of Operative Gynecology for treating malignant vulvar neoplasma. She was reffered to our clinic for electrocauterization after being diagnosed of condylomata accuminata. Physical examination revealed vulva atrophy with smooth discolored skin patches on both sides. A 2 cm exophytic lesion was noted ~10 mm from clitoris on right labia majora. Multifocal biopsy was performed for suspect finding which proved invasive vulvar squamous keratinizing cancer. Positron emission tomography-computed tomography (PET/CT) scan showed individual lymph nodes on right inguinofemoral region which were moderately metabolically active. Wide excision of cancer was performed with unilateral inguinofemoral lymphadenectomy. Macroscopic evaluation of entire specimen depicted 2.4 × 2.2 × 0.5 cm HPV associated invasive vulvar squamous keratinizing cancer, vulvar high grade squamous intraepithelial lesion (vHSIL) or usual type vulvar intraepithelial neoplasia (uVIN3) and lichen sclerosus. Healthcare professionals in primary care centers should be adequately trained, aware of and familiar with vulvar malignancies in younger women despite their rarity. Early diagnosis can improve outcomes in vulvar cancer via reducing morbidity and mortality. The individualized surgical treatment is the preferred strategy for patients at present.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135311277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic primary tumor factors associated with risk of pelvic and paraaortic lymph node involvement in patients with endometrial adenocarcinoma","authors":"","doi":"10.22514/ejgo.2023.056","DOIUrl":"https://doi.org/10.22514/ejgo.2023.056","url":null,"abstract":"The presence of lymph node (LN) positivity in endometrial adenocarcinoma (EAC) patients guides adjuvant treatment, but recommendations regarding LN evaluation at the time of primary surgery remain variable. Primary pathologic tumor characteristics may predict risk of LN involvement in EAC patients with limited LN evaluation. Patients diagnosed between 2004–2016 with pathologic T1–T2 EAC in the National Cancer Database who had at least one lymph node sampled at the time of surgery were included. Pathologic primary tumor predictors of LN involvement were identified using logistic regression. To predict overall, pelvic only, and paraaortic and/or pelvic LN involvement, nomograms were generated. Among 57,810 EAC patients included, 4002 were node positive. On multivariable analysis, increasing pathologic tumor category (pT2 versus pT1a, odds ratio (OR) 5.43, 95% confidence interval (CI) 4.89–6.02, p < 0.001), increasing pathologic tumor grade (grade 3 versus grade 1, OR 1.62, 95% CI 1.47–1.79, p < 0.001), increase in tumor size per centimeter (OR 1.05, 95% CI 1.04–1.06, p < 0.001), and presence of lymphovascular invasion (LVI) (OR 6.33, 95% CI 5.87–6.83, p < 0.001) were predictive of overall LN positivity. The presence of LVI was a stronger predictor of paraaortic LN involvement (OR 6.43, 95% CI 5.55–7.47, p < 0.001) than pelvic LN involvement (OR 5.42, 95% CI 4.98–5.90, p < 0.001) in multivariable analysis. For patients with limited LN evaluation, pathologic tumor features can be used to estimate the risk of pelvic or paraaortic LN involvement. This information may inform adjuvant treatment decisions and guide future studies.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro","authors":"","doi":"10.22514/ejgo.2023.081","DOIUrl":"https://doi.org/10.22514/ejgo.2023.081","url":null,"abstract":"Endometrial cancer (EC) includes several epithelial malignancies existed in the endometrium tissues. To improve the prognosis of EC, it is greatly needed to find new drugs. Dezocine, a organic compound, is an κ agonist and a µ receptor antagonist, is used in clinical anesthesia after cancer surgery with few side effects, and its anti-tumor effects have also been demonstrated in several tumors. However, the effects of Dezocine on EC progression have not been elusidated. Herein, we investigated the role of Dezocine in EC cell functions. Through a series of cellular assays, such as cell counting kit-8 (CCK-8), flow cytometry (FCM), transwell assays, we found that Dezocine suppressed the EC cell proliferation, and stimulated EC cell apoptosis in vitro. Furthermore, results revealed Dezocine restrained the motility, including migration and invasion of EC cells. Mechanically, Dezocine suppressed the Akt (protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway in EC cells, thereby suppressing EC cell proliferation as well as migration in vitro. In conclusion, Dezocine inhibits proliferation as well as migration of EC in vitro.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of ultrasonic parameters combined with clinicopathological parameters in predicting axillary lymph node metastasis in triple-negative breast cancer","authors":"","doi":"10.22514/ejgo.2023.084","DOIUrl":"https://doi.org/10.22514/ejgo.2023.084","url":null,"abstract":"The clinical data of 119 patients with triple-negative breast cancer (TNBC) were retrospectively analyzed, and comparisons revealed that the differences between those who developed axillary lymph node metastasis and those who did not were statistically significant when comparing the age, histological grading of the lesions, expression of Ki-67, and information about the morphology of the lesions, internal blood flow, and the ultrasonographic manifestations of axillary lymph nodes on ultrasonography of the distribution of the lesions in the lesions’ quadrants (p < 0.05). Multifactorial regression analysis suggested that age, histological grade, lesion quadrant, and axillary lymph node ultrasound performance were all relevant factors affecting axillary lymph node metastasis in TNBC patients; the predictive model of axillary lymph node metastasis in TNBC was constructed with the results of multifactorial regression analysis, and the results of the ROC curve analysis showed that the logistic regression model had an AUC of 0.761 and the sensitivity and specificity were 0.824 and 0.714, respectively, for predicting the metastasis of the axillary lymph nodes in TNBC patients. This suggests that ultrasound combined with pathological parameters has some value in helping clinical judgment of axillary lymph node metastasis in TNBC patients.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLUT1-mediated magnetic liposomes for targeting bone metastatic breast cancer","authors":"Ze Zhao, Yi Zhao, Chang Chen, Changwei Xie, Ask Verbruggen, E Mccarthy, R Dwyer, L Mcnamara, Z Zhao, Y Zhao, C Xie, C Chen, D Lin, S Wang, B Luo, Y Yuan, Y Zhu, S Liang, R Dong, J Hou, A Isik, A Soran, A Grasi, N Barry, E Sezgin, A Ik, A Grassi, A Soran, Y Yang, Z Zhao, C Xie, Y Zhao, X Zhang, Q Liu, T Zhang, P Gao, H Wang, L Yao, L Hendriks, B Hermans, M Van Den Beuken-Van Everdingen, M Hochstenbag, A Dingemans, Z Zhao, C Chen, C Xie, Y Zhao, X Mu, M Zhang, A Wei, F Yin, Y Wang, K Hu, H Shao, H Shao, P Varamini, S Bose, C Zhang, A Le, Y Zhao, Y Peng, Z Yang, J Lu, R Li, Y Shi, Y Zhao, Z Zhao, Y Cui, X Chen, C Chen, C Xie, F Siyal, Z Memon, R Siddiqui, Z Aslam, U Nisar, R Imad, B Han, Y Yang, J Chen, H Tang, Y Sun, Z Zhang, R Chen, X Chen, Y Zhou, T Lin, Y Leng, X Huang, Y Peng, Y Gao, C Yang, R Guo, X Shi, X Cao, L Zhang, Y Zhao, Q Yue, Q Fu, L Hai, L Guo, M Zhu, X Liu, Y Qu, S Hu, Y Zhang, W Li, J Kim, S Lee, H Kim, Y Choi, J Yoo, K Park","doi":"10.22514/ejgo.2023.012","DOIUrl":"https://doi.org/10.22514/ejgo.2023.012","url":null,"abstract":"Bone metastatic breast cancer is a malignant tumor in bone due to the metastasis of breast cancer, and its incidence is increasing worldwide. Treatment of cancer metastasized to bone is still a challenge because of the anticancer drugs lack target specificity. Finding an effective treatment for bone metastasis remains an urgent issue. In order to enhance the delivery of paclitaxel (PTX) to the bone metastases lesions, a novel glucose derivative was designed and synthesized in this work, which was used as liposome ligand to develop the magnetic liposome G-MLip (Glucose-modified magnetic liposome). The liposome could improve the drug formulations in the bone metastases mediated by glucose transporter 1 (GLUT1) and then target cancer cells. The PTX-loaded magnetic liposome PTX-G-MLip was prepared by the film hydration-ultrasound method. And the characterizations, such as size, zeta potential, encapsulation efficiency, release profile, stability, hemolysis, were well evaluated. What’s more, the enhanced target ability was also investigated in vitro and in mice. The metastatic bone-targeted capacity was confirmed that the PTX concentration from PTX-G-MLip in the bone metastases lesions was markedly increased in the presence of magnetic field (MF) compared with the free PTX and other liposomes. Inspired by the enhanced targeting ability, glucose-modified magnetic liposomes could serve as an effective drug delivery system for targeting and treating bone metastases.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20230215-1427/pdf/EJGO2022092301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147880107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway","authors":"Huan Xiao, Chunqing Wei, Dan Peng, Yuge Guo, Yuge Guo, L Zhang, Y Wan, Z Zhang, Y Jiang, Z Gu, X Ma, B Rak, J Marczewska, P Wlodarski, A Felix, J Weissfeld, R Edwards, F Linkov, A Tran, P Gehrig, Y Wang, L Yin, X Sun, Y Sonoda, R Sun, X Sun, H Liu, P Li, C Kong, Z Zhu, Y Li, P Xue, L Chen, Q Li, C Wang, Dong Su, Y Ma, Z, T Liu, X Wang, J Zhai, Q Wang, B Zhang, H Liao, R Winkfein, G Mack, J Rattner, T Yen, X Zhu, M Mancini, K Chang, C Liu, C Chen, B Shan, J Sun, J Huang, J Lan, K Zhou, Y Gao, Z Song, Y Huang, D Li, L Wang, X Su, X Tang, S O'brien, A Fagan, Ejp Fox, R Millikan, A Culhane, D Brennan, X Yang, B Miao, C Wei, R Dong, P Gao, X Zhang, E Chen, X Qin, K Peng, Q Li, C Tang, Y Wei, Y Liu, P Chen, M Li, H Fei, J Huang, T Zhao, B Shorning, M Dass, M Smalley, H Pearson, M Ediriweera, K Tennekoon, S Samarakoon, A Guerrero-Zotano, I Mayer, C Arteaga, B Slomovitz, R Coleman, Y Zhang, F Zhang, Y Zhang, K Thakur, J Zhang, Y Liu, I Hsin, H Shen, H Chang, J Ko, P Wang, D Chandrashekar, B Bashel, Sah Balasubramanya, C Creighton, I Ponce-Rodriguez, Bvsk Chakravarthi, S Ling, L Zhang, Y Qian, Z Liu, Z Mao, Q Zhang, X Yang, J Gong, X Cai, Y Yuan, X Wang, T Chen, Z Deng, W Gao, T Liang, X Qiu, M Sang, M Wu, L Meng, Y Zheng, L Gu, F Liu, Q Chen, H Xu, J Zhu, K Feng, C Hu, Y Han, S Xu, K Cheng, C Diao, S Liu, W Zou, R Edgar, M Domrachev, A Lash, M Shahid, M Kim, M Lee, A Yeon, S You, H Kim, J Yuan, L Gu, L Chen, Y Yin, Fan, P Li, S You, C Nguyen, Y Wang, J Kim, D Sirohi, J Zhou, Y Jiang, H Chen, Y Wu, L Zhang, S Shahcheraghi, V Tchokonte-Nana, M Lotfi, M Lotfi, A Ghorbani, H Sadeghnia, F Roncolato, K Lindemann, M Willson, Martyn Mileshkin, L, H Liu, L Zhang, X Zhang, Z Cui","doi":"10.22514/ejgo.2023.013","DOIUrl":"https://doi.org/10.22514/ejgo.2023.013","url":null,"abstract":"Centromere protein F (CENPF) has been found to exert vital roles in various cancers, while the detailed effect of CENPF on endometrial cancer (EC) remains unclear. This study indicated that CENPF was up-regulated in EC tissue samples using The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and Gene Expression Profiling Interactive Analysis (GEPIA) database. Quantitative real time polymerase chain reaction and western blotting assays confirmed the increased CENPF in EC cells. In addition, overexpression of CENPF promoted cell proliferation, whereas CENPF knockdown notably suppressed the proliferation of EC cells, demonstrated by Methyl Thiazolyl Tetrazolium (MTT) as well as colony formation assays. Moreover, CENPF overexpression accelerated cell cycle, migration ad invasion, whereas CENPF knockdown contributed to cell cycle arrest at G2 stage and suppressed migration and invasion in EC cells. Furthermore, western blotting analysis demonstrated that CENPF overexpression up-regulated the content of phosphorylated protein kinase B (p-AKT), phosphorylated phosphatidylinositol 3-kinase (p-PI3K), and phosphorylated mechanistic target of rapamycin kinase (p-mTOR), while CENPF silencing notably decreased their levels, indicating that CENPF positively regulated PI3K/AKT/mTOR signaling in EC cells. In summary, this study verified that CENPF promoted EC cells progression by mediating PI3K/AKT/mTOR cascade signal in EC cell lines.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20230215-1428/pdf/EJGO2022018.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147894274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the mechanism of Zhimu in the treatment of ovarian cancer based on network pharmacology","authors":"","doi":"10.22514/ejgo.2023.059","DOIUrl":"https://doi.org/10.22514/ejgo.2023.059","url":null,"abstract":"We aimed to investigate the mechanism of action of Zhimu in the treatment of ovarian cancer (OC) using network pharmacology. OC targets were screened using the DisGeNET and Online Mendelian Inheritance in Man databases. Common OC and Zhimu targets were identified using the Traditional Chinese Medicine System Pharmacology, UniProt databases, and Venny 2.1.0. The protein-protein interaction (PPI) network in the Search Tool for the Retrieval of Interacting Genes/Proteins database was created using Zhimu/OC targets and a Zhimu active ingredient-target-pathway network in the Cytoscape 3.9.1 software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted using the Metascape database. And overall, 15 active ingredients in addition to 93 related targets were identified. The PPI network had 52 targets that overlapped with it, with the 10 most relevant targets being the tumour protein p53, tumour necrosis factor, serine/threonine kinase 1, vascular endothelial growth factor A, caspase-3, prostaglandin G/H synthase-2, hypoxia-inducible factor-1 alpha, interleukin-1 beta, heat-shock protein 90-alpha, and progesterone receptor. According to GO and KEGG analyses, Zhimu and OC had the nuclear factor NF-kappaB signalling pathway, oxidative stress, and the advanced glycation end product (AGE)/the receptor for the advanced glycation end product (RAGE) signalling pathway as common targets. This study highlighted the active ingredients in Zhimu and identified potential molecular therapeutic mechanisms for the treatment of OC. It also provided suggestions and directions for future research into molecular mechanisms.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of percutaneous nephrostomy on clinical outcomes in advanced carcinoma cervix with obstructive uropathy at Kenyatta national hospital","authors":"","doi":"10.22514/ejgo.2023.075","DOIUrl":"https://doi.org/10.22514/ejgo.2023.075","url":null,"abstract":"This retrospective study aimed to determine the impact of percutaneous nephrostomy (PCN) on the quality of life (QOL) and kidney function of women with advanced carcinoma of the cervix and obstructive uropathy in Kenyatta National Hospital by utilizing data from 2016 to 2019 and a follow-up patient interview in 2020. Sociodemographic data from patient records was reported as descriptive statistics. Serum urea, hemoglobin and creatinine levels before PCN and 72 hours, 1 month and 3 months after PCN were obtained. The changes were analysed using a paired t-test. Quality of life data before and after PCN tube insertion were collected using the structured Functional Assessment of Cancer Therapy and a cervix cancer-specific subscale (FACT-Cx) questionnaire, responses scored and an aggregate tallied. The QOL and kidney function data variables before and after PCN tube insertion were compared with statistical significance set at p < 0.05. Fifty eight study participants were enrolled, with an 80% power to detect a 5 fold change in kidney function. Percutaneous nephrostomy had an overall improvement in the quality of life (FACT-Cx total p = 0.041) with changes in aspects of physical well-being (p = 0.018) and additional concerns sexual function, self-esteem, appearance, urinary function, appetite and gastrointestinal function (p ≤ 0.001); but none in other aspects of the tool. Improvement was noted 72 hours after PCN tube insertion in 62% of patients’ urea (p = 0.033) and 64% of creatinine (p ≤ 0.001) levels but not sustained after 1 month and did not revert to normal levels. Hemoglobin levels did not improve. Percutaneous nephrostomy was found to have a short-term added value in management of women with obstructed uropathy in advanced carcinoma of the cervix as two aspects of their QOL improved while serum urea and creatinine levels improved slightly with no functional recovery.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential mechanism of Astragalus polysaccharide increasing chemosensitivity of cervical cancer HeLa cells to carboplatin by modulating the PI3K/Akt signaling pathway","authors":"Wenzhi Liu, Lu Zhang, Minmin Yu, D Song, W Kong, T Zhang, C Han, T Liu, S Jiao, A Choudhari, P Mandave, M Deshpande, P Ranjekar, O Prakash, Y Guo, Z Zhang, Z Wang, G Liu, Y Liu, H Wang, O Bamodu, K-T Kuo, C-H Wang, W-C Huang, Ath Wu, J-T Tsai, W-C Huang, K-T Kuo, O Bamodu, Y-K Lin, C-H Wang, K-Y Lee, C Wu, Y Ke, Y Zeng, Y Zhang, H Yu, C Li, L Hong, C Liu, J Min, M Hu, W Guo, Y Tan, L Yin, Z Sun, S Shao, Chen Man, X, Q Zhai, X Hu, Xiao Yu, D, Y Shi, X Feng, L Xie, X Wang, Z Zhang, Z Wang, M Hao, T Li, Q Zhou, W Zhang, W Liu, G Li, H Zhou, Y Liu, M Luo, Z Lin, C Porta, C Paglino, A Mosca, P Xia, X-Y Xu, M Aoki, T Fujishita, T Ersahin, N Tuncbag, R Cetin-Atalay, E Lien, C Dibble, A Toker, S Noorolyai, N Shajari, E Baghbani, S Sadreddini, B Baradaran, Q Yang, W Jiang, P Hou, S Pompura, M Dominguez-Villar, Y Xie, X Shi, K Sheng, G Han, W Li, Q Zhao, J Karar, A Maity, Y Cao, Y Ruan, T Shen, X Huang, M Li, W Yu, Y Zhang, L Wang, M Du, S Sun, X He, D Luo, C Lv, S Jing, A Lv, M Zhang, W Li, P Zhao, W Gao, L Huo, A Sui, M Zhang, C Zhang, X Liu, W Li, W Gao, A Sui, Y Yang, Z Lin, P He, H Nie, Q Yao, S Zhang, L Guo, S Bai, L Zhao, X Wang, Q Tian, M Yan, H Cai, Q Tan, W Zhang","doi":"10.22514/ejgo.2023.093","DOIUrl":"https://doi.org/10.22514/ejgo.2023.093","url":null,"abstract":"The current study investigated the possible mechanisms in which astragalus polysac-charide (APS) elevates the chemosensitivity of cervical cancer (CC) HeLa cells to carboplatin (CBP) by regulating the PI3K/Akt pathway. In this study, HeLa cells were assigned to the control, CBP, APS, and APS + CBP groups, and the proliferation of HeLa cells in each group was detected using the MTT (methyl thiazolyl tetrazolium) assay. The apoptosis and cycle of HeLa cells were examined using flow cytometry, and the expression levels of PI3K (phosphatidylinositol-3-kinases), Akt (Protein Kinase B), p-PI3K (phospho-phosphatidylinositol-3-kinases), and p-Akt (phospho-Akt) proteins in the PI3K/Akt pathway were determined using Western blot. MTT results revealed that the inhibitory effect was more significant within the APS + CBP groups (p &lt; 0.01). The flow cytometry results showed that the apoptosis rate was significantly elevated in the APS + CBP groups (p &lt; 0.01). Compared with the control group, the most prominent arrest in the G2/M phase and the arrest within the G2/M phase in the APS + CBP groups being the most significant. Western-blot results depicted that the above proteins in the APS + CBP groups revealed more significant expression changes (p &lt; 0.01). The above analyses demonstrated that APS could increase the chemosensitivity of CC HeLa cells to CBP by modulating the PI3K/Akt pathway. In conclusions, it is reasonable to believe that the enhancing effect of APS on the sensitivity of chemotherapeutic drugs was associated with blocking the PI3K/Akt pathway, thus, enhancing.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"44 6","pages":"4-4"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20231215-112/pdf/EJGO2022111501.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147889944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer","authors":"W. Wang, M. Gao, Xiaoting Li, Hong Zheng, Yu-nong Gao","doi":"10.31083/j.ejgo4302030","DOIUrl":"https://doi.org/10.31083/j.ejgo4302030","url":null,"abstract":"Objectives : To investigate the effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer. Methods : A retrospective study was performed among 210 patients with advanced ovarian cancer who were treated with neoadjuvant chemotherapy from May 1, 2007 to December 1, 2015. 121 patients with NACT-IDS (Neoadjuvant chemotherapy followed by interval debulking surgery) were enrolled. The patients were divided into observation group (NACT-IDS + IP group, n = 28) and control group (NACT-IDS + IV group, n = 93) depending on whether intraperitoneal chemotherapy was used after interval debulking surgery. The effects of intraperitoneal chemotherapy after NACT-IDS on PFS (progression-free survival) and OS (overall survival) were analyzed and the influencing factors were explored through multivariate analysis. The competitive model was used to analyze the effect of intraperitoneal chemotherapy after NACT-IDS on tumor recurrence. Toxicities associated with adjuvant chemotherapy were also analyzed between two groups. The effect of neoadjuvant chemotherapy cycles on prognosis and the correlation between postoperative CA125 decline and recurrence were evaluated. Results : Intraperitonal chemotherapy and R0 (no gross residual) were independent factors for PFS, with HRs of 0.560 (95% CI, 0.342–0.918, p = 0.022) and 0.578 (95% CI, 0.377–0.887, p = 0.012). There was no independent factor associated with OS. Significant difference in PFS was detected among the R0 + IP group, R0 + IV group, non-R0 + IP group and non-R0 + IV group. In patients with R0 tumor reduction, IP patients showed significantly better PFS, bonferronei adjusted p = 0.036. In patients without R0 tumor reduction, no significant difference was detected between IP and IV group, bonferronei adjusted p = 0.28. There were no significant differences of grade 3–4 toxicities, abdominal pain, treatment delays, dose reductions, and treatment modifications in NACT-IDS + IP group and NACT-IDS + IV group. Neoadjuvant chemotherapy cycles ( ≤ 3 and > 3) were not the influencing factors of PFS or OS and did not affect platinum-sensitive relapse or platinum-resistant relapse. The decrease in postoperative CA125 was not related to platinum-sensitive recurrence or platinum-resistant recurrence. Conclusions : Neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval debulking surgery could improve the PFS of patients with advanced epithelial ovarian cancer compared to intravenous chemotherapy without significant differences in toxicity.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47261060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}